ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-4931ometendo-4931Research ArticleСтатьиArticlesУспешное лечение акромегалии Соматулином: нейроэндокринные и метаболические аспектыUspeshnoe lechenie akromegalii Somatulinom: neyroendokrinnye i metabolicheskie aspektyDzeranovaL K-TabeevaK I-VorontsovA V-VladimirovaV P-20051506200522№2 (2005)4749Copyright © Dzeranova L.K., Tabeeva K.I., Vorontsov A.V., Vladimirova V.P., 20052005Dzeranova L.K., Tabeeva K.I., Vorontsov A.V., Vladimirova V.P.Dzeranova L.K., Tabeeva K.I., Vorontsov A.V., Vladimirova V.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/4931ReferencesВакс В.В. Диагностика и лечение акромегалии. // Лечащий врач 2004, 6,8-14.Вакс В.В. Диагностика и лечение акромегалии. // Лечащий врач 2004, 6,8-14.Дедов И.И., Вакс В.В. Аналоги соматостатина в лечении опухолей нейроэндокринной системы. // Проблемы эндокринологии 2004, 6, 50,42-48.Дедов И.И., Вакс В.В. Аналоги соматостатина в лечении опухолей нейроэндокринной системы. // Проблемы эндокринологии 2004, 6, 50,42-48.Калинин А.В. Новое в онкогенезе, диагностике и лечении нейроэндокринных опухолей желудочно-кишечного тракта и поджелудочной железы. // Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 1998 (6), 13-17.Калинин А.В. Новое в онкогенезе, диагностике и лечении нейроэндокринных опухолей желудочно-кишечного тракта и поджелудочной железы. // Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 1998 (6), 13-17.Марова Е.И., Пронин В.С., Агаджанян С.Э., Молитвословова Н.Н., Вакс В.В., Анциферов М.Б. Медико-социальные проблемы курации больных с акромегалией. // Consilium Medicum 2004, 6,9.Марова Е.И., Пронин В.С., Агаджанян С.Э., Молитвословова Н.Н., Вакс В.В., Анциферов М.Б. Медико-социальные проблемы курации больных с акромегалией. // Consilium Medicum 2004, 6,9.Altstadt T.J., Azzarelli B at al. Acromegaly caused by a growth hormone-releasing hormone-secreting carcinoid tumor. // Neurosergery 2002 50(6), 1356-9.Altstadt T.J., Azzarelli B at al. Acromegaly caused by a growth hormone-releasing hormone-secreting carcinoid tumor. // Neurosergery 2002 50(6), 1356-9.Attanasio R, Baldelli R, Pivonello R at al. Lanreotide 60 mg, a new long-acting for- mulation: effectiveness in the chronic treatment of acromegaly. // Clin Endocrinol Metab. 2003;88(11):5258-65.Attanasio R, Baldelli R, Pivonello R at al. Lanreotide 60 mg, a new long-acting for- mulation: effectiveness in the chronic treatment of acromegaly. // Clin Endocrinol Metab. 2003;88(11):5258-65.Baldelli R, Battista C, Leonetti F at al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf). 2003;59(4):492-9.Baldelli R, Battista C, Leonetti F at al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf). 2003;59(4):492-9.Baldelli R, Durante C, D'Amico E at al. Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. // J Endocrinol Invest. 2003;26(12):1219-24.Baldelli R, Durante C, D'Amico E at al. Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. // J Endocrinol Invest. 2003;26(12):1219-24.Bondanelli M, Ambrosio MR, Zatelli MC at al. Regression of liver metastases of 49 occult carcinoid tumor with slow release lanreotide therapy.// World J Gastroenterol. 2005, 7;11(13):2041-4.Bondanelli M, Ambrosio MR, Zatelli MC at al. Regression of liver metastases of 49 occult carcinoid tumor with slow release lanreotide therapy.// World J Gastroenterol. 2005, 7;11(13):2041-4.Colao A, Marzullo P, Lombardi G at al. Effect of a six-month treatment with lan- reotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. // Eur J Endocrinol. 2002 146(3):303-9.Colao A, Marzullo P, Lombardi G at al. Effect of a six-month treatment with lan- reotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. // Eur J Endocrinol. 2002 146(3):303-9.Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to deport somato- statin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. // Clin Endocrinol 2004, 61/2, 209-215.Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to deport somato- statin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. // Clin Endocrinol 2004, 61/2, 209-215.Hofland LJ, Lamberts SW. Somatostatin receptors in pituitary function, diagnosis and therapy. // Front Horm Res. 2004;32:235-52.Hofland LJ, Lamberts SW. Somatostatin receptors in pituitary function, diagnosis and therapy. // Front Horm Res. 2004;32:235-52.Gutt B, Bidlingmaier M, Kretschmar K at al. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).// Exp Clin Endocrinol Diabetes. 2005;113(3):139-44.Gutt B, Bidlingmaier M, Kretschmar K at al. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).// Exp Clin Endocrinol Diabetes. 2005;113(3):139-44.Ronchi CL, Orsi E, Giavoli C at al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. // J Endocrinol Invest. 2003; 26(6):533-8.Ronchi CL, Orsi E, Giavoli C at al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. // J Endocrinol Invest. 2003; 26(6):533-8.Vance ML, Laws ER Role of medical therapy in the management of acromegaly. // Neurosurgery 2005, 56(5): 877-85.Vance ML, Laws ER Role of medical therapy in the management of acromegaly. // Neurosurgery 2005, 56(5): 877-85.Weckbecker G., Lewis I., Albert R at al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. // Nature Reviews Drug Discovery 2003, 2, 12 999-1017.Weckbecker G., Lewis I., Albert R at al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. // Nature Reviews Drug Discovery 2003, 2, 12 999-1017.
The authors declare that there are no conflicts of interest present.